Showing results (161-170 of 218) with videos related to
Sort By:
Pageof 22
Science (New York, N.Y.)|January 6, 2018
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinomaDiana Miao, Claire A Margolis, Wenhua Gao, et al.The New England Journal of Medicine|September 29, 2019
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung CancerMatthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancersJ K Sabari, G C Leonardi, C A Shu, et al.The New England Journal of Medicine|April 21, 2015
Pembrolizumab for the treatment of non-small-cell lung cancerEdward B Garon, Naiyer A Rizvi, Rina Hui, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as BiomarkersNeal Ready, Matthew D Hellmann, Mark M Awad, et al.Cell|January 28, 2021
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibitionKevin Litchfield, James L Reading, Clare Puttick, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2020
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50J F Gainor, H Rizvi, E Jimenez Aguilar, et al.Nature|March 22, 2019
Neoantigen-directed immune escape in lung cancer evolutionRachel Rosenthal, Elizabeth Larose Cadieux, Roberto Salgado, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2023
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung CancerRohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2017
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)Leora Horn, David R Spigel, Everett E Vokes, et al.Pageof 22